Pharmabiz1 uair an chloig
Bayer’s subsidiary, Vividion acquires Tavros Therapeutics to expand functional genomics capabilities and boost drug discovery platform
San Diego, California Friday, January 10, 2025, 10:00 Hrs [IST] ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer attacked bureaucracy by firing some 5,000 managers and asking teams to ‘self-organize.’ Here’s how it’s going after one year
Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...
The Pharma Letter15 uair an chloig
Bayer Phase III success with elinzanetant
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...
pharmaphorum1 lá
Bayer applies artificial intelligence to its pharmacovigilance systems
The German pharmaceutical company has tied ... its Pharmacovigilance Artificial Intelligence (PVAI) products. These will be added to Bayer's existing pharmacovigilance database and IT systems ...
Bayer aims to expand presence in India with new therapies and strategic collaborations
Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...
Bayer: Sell And Be Done With It
Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...
Daily1 lá
Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer
Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...
Wall Street Journal23 lá
Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
Bayer BAYN0.33%increase; green up pointing triangle said its eye treatment aflibercept at high doses showed positive results in a late-stage trial, including improved vision gains for people ...
ncbiotech.org1 lá
Durham’s Tavros Therapeutics sold to subsidiary of German giant Bayer AG
Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...